Skip to main content
Premium Trial:

Request an Annual Quote

Genoptix Licenses Rights to HistoRx Aqua Tech

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Lab services provider Genoptix said today that it has signed a license and collaboration agreement with HistoRx covering cancer biomarker analysis technologies in the US.

The license gives Carlsbad, Calif.-based Genoptix the exclusive commercial laboratory rights to develop and perform in the US three solid tumor assays using HistoRx's Aqua technology. In addition, it has gained non-exclusive rights to use Aqua to measure two other biomarkers that have been associated with many cancers.

The Aqua technology is used in fluorescent immunohistochemstry analysis, and enables users to assess specific biomarkers for patients with solid tumors by measuring the protein in a cell's cytoplasm or nucleus.

Under the agreement, Genoptix and HistoRx may collaborate to develop additional assays that Genoptix would then have the rights to commercialize. Financial terms of the agreement were not released.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.